These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30420758)

  • 1. Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes.
    Jiao Y; Davis JE; Rautela J; Carrington EM; Ludford-Menting MJ; Goh W; Delconte RB; Souza-Fonseca-Guimaraes F; Koldej R; Gray D; Huang D; Kile BT; Lew AM; Ritchie DS; Huntington ND
    Cell Death Differ; 2019 Aug; 26(8):1516-1530. PubMed ID: 30420758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients.
    Davis JE; Du K; Ludford-Menting MJ; Prabahran A; Wong E; Huntington ND; Koldej RM; Ritchie DS
    Front Immunol; 2021; 12():749094. PubMed ID: 34630428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
    He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.
    Davis JE; Harvey M; Gherardin NA; Koldej R; Huntington N; Neeson P; Trapani JA; Ritchie DS
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):242-9. PubMed ID: 25459639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor NK Cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation.
    Hu B; Bao G; Zhang Y; Lin D; Wu Y; Wu D; Liu H
    J Immunol; 2012 Aug; 189(4):1661-70. PubMed ID: 22798668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.
    Ruggeri L; Mancusi A; Burchielli E; Capanni M; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
    Blood Cells Mol Dis; 2008; 40(1):84-90. PubMed ID: 17964828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
    Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.
    Barge RM; Osanto S; Marijt WA; Starrenburg CW; Fibbe WE; Nortier JW; Falkenburg JH; Willemze R
    Exp Hematol; 2003 Oct; 31(10):865-72. PubMed ID: 14550801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.
    Wang F; Zhao S; Gu Z; Zhao X; Yang N; Guan L; Liu T; Wang L; Fang S; Zhu C; Luo L; Li M; Wang L; Gao C
    Hematol Oncol; 2020 Feb; 38(1):89-102. PubMed ID: 31465552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo.
    Johnson BD; Truitt RL
    Transplantation; 1992 Jul; 54(1):104-12. PubMed ID: 1631918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
    Yu JP; Cao S; Xin N; An XM; Qi J; Ren XB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1013-8. PubMed ID: 17956681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Ruggeri L; Capanni M; Urbani E; Perruccio K; Shlomchik WD; Tosti A; Posati S; Rogaia D; Frassoni F; Aversa F; Martelli MF; Velardi A
    Science; 2002 Mar; 295(5562):2097-100. PubMed ID: 11896281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.